IRulya Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IRulya Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 94% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-119.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 84% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-2.3×Operating cash was negative last year, while some debt falls due within a year.
Higher than 63% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 70% of Healthcare companies in United States.
Tangible Assets Ratio
27%Of every $100 the company owns, $27 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 94% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
IRulya Therapeutics Inc. made a loss over the last year. IRulya Therapeutics Inc. owes $1.28 for every $1 it owns. IRulya Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossIRulya Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
-0.95IRulya Therapeutics Inc.'s book value is negative (it owes more than it owns), so P/B is not meaningful.
Market cap
$34 MThe total market value of all of IRulya Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 78% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
NegativeIRulya Therapeutics Inc.'s net worth is negative ($35 M below zero, balance sheet 30 Jun 2026): it owes more than it owns, so book value per share and P/B are not meaningful.
Return on equity (ROE)
-153.8%IRulya Therapeutics Inc. lost 153.8% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
Owes vs Owns
1.28×IRulya Therapeutics Inc. owes $1.28 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Dividend yield
NoneIRulya Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossIRulya Therapeutics Inc. made a loss in each of the last two years.
Cash vs debt
Net debtIRulya Therapeutics Inc. had $1 M more debt than cash (net debt) at Dec 2025.
Questions
What is IRulya Therapeutics Inc.'s return on equity?
IRulya Therapeutics Inc. lost 153.8% of its shareholders' money over the last year, lower than 80% of Healthcare companies in United States.
How much does IRulya Therapeutics Inc. owe compared with what it owns?
IRulya Therapeutics Inc. owes $1.28 for every $1 it owns, so it owes more than it owns, higher than 92% of Healthcare companies in United States.
Does IRulya Therapeutics Inc. pay a dividend?
No. IRulya Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.